###begin article-title 0
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
###end article-title 0
###begin p 1
Conceived and designed the experiments: CAO TB. Performed the experiments: CAO LIP CG ARG MRA AR MLB ES RSW. Analyzed the data: CAO LIP CG RLJ RSW SCM TB. Contributed reagents/materials/analysis tools: CAO JJG AR CT TB. Wrote the paper: CAO TB.
###end p 1
###begin p 2
###xml 408 423 <span type="species:ncbi:10090">transgenic mice</span>
Osteocytes, former osteoblasts buried within bone, are thought to orchestrate skeletal adaptation to mechanical stimuli. However, it remains unknown whether hormones control skeletal homeostasis through actions on osteocytes. Parathyroid hormone (PTH) stimulates bone remodeling and may cause bone loss or bone gain depending on the balance between bone resorption and formation. Herein, we demonstrate that transgenic mice expressing a constitutively active PTH receptor exclusively in osteocytes exhibit increased bone mass and bone remodeling, as well as reduced expression of the osteocyte-derived Wnt antagonist sclerostin, increased Wnt signaling, increased osteoclast and osteoblast number, and decreased osteoblast apoptosis. Deletion of the Wnt co-receptor LDL related receptor 5 (LRP5) attenuates the high bone mass phenotype but not the increase in bone remodeling induced by the transgene. These findings demonstrate that PTH receptor signaling in osteocytes increases bone mass and the rate of bone remodeling through LRP5-dependent and -independent mechanisms, respectively.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 432 435 432 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Parfitt1">[1]</xref>
###xml 630 633 630 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Nijweide1">[2]</xref>
###xml 635 638 635 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bonewald1">[3]</xref>
###xml 796 799 796 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Marotti1">[4]</xref>
###xml 972 975 972 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Tatsumi1">[5]</xref>
###xml 1170 1173 1170 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Weinstein1">[6]</xref>
###xml 1174 1178 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Tomkinson2">[11]</xref>
###xml 1248 1252 1248 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-OBrien1">[12]</xref>
Bone remodeling maintains the integrity of the skeleton by continuously replacing packets of old bone with new through the coordinated action of two cell types: osteoclasts that resorb bone, followed by osteoblasts that form bone. The rate of bone remodeling is determined by the number of osteoclasts and osteoblasts; whereas the amount of bone present in the skeleton is determined by the balance between resorption and formation [1]. Osteocytes, former osteoblasts buried within the bone matrix during the process of bone deposition, are distributed throughout bone in numbers that far exceed either osteoclasts or osteoblasts [2], [3]. Osteocytes are connected with each other and with cells on the bone surface via cytoplasmic processes that travel along tunnels within the mineralized bone [4]. Through this extensive network, osteocytes sense variations in the level of mechanical forces acting on bone and respond by signaling to osteoblasts, osteoclasts, or both [5]. Osteocytes also perceive changes in the levels of systemic factors as evidenced by the increased prevalence of osteocyte apoptosis that occurs with glucocorticoid excess or estrogen withdrawal [6]-[11], and increased osteocyte apoptosis may itself decrease bone strength [12]. However, whether hormones influence bone mass or the rate of bone remodeling via actions on osteocytes has heretofore been unknown.
###end p 4
###begin p 5
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Winkler1">[13]</xref>
###xml 94 98 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Poole1">[16]</xref>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Balemans1">[17]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Brunkow1">[18]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Li1">[19]</xref>
###xml 538 542 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Ke1">[20]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Winkler1">[13]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Loots1">[21]</xref>
###xml 951 955 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Glass1">[25]</xref>
###xml 956 960 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Almeida1">[27]</xref>
###xml 133 139 <span type="species:ncbi:9606">humans</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 556 571 <span type="species:ncbi:10090">transgenic mice</span>
Sclerostin, the product of the Sost gene, is expressed exclusively by osteocytes in bone [13]-[16]. Loss of sclerostin expression in humans results in the high bone mass disorders Van Buchem's disease [17] and sclerosteosis [18], providing compelling evidence that osteocytes can control bone mass. Moreover, targeted deletion of the Sost gene in mice results in increased bone formation and strength [19]; and administration of an anti-sclerostin antibody increases bone formation and restores the bone lost after ovariectomy in rodents [20]. Conversely, transgenic mice overexpressing Sost exhibit low bone mass [13], [21]. Sclerostin acts in a paracrine manner to inhibit bone formation by binding to the Wnt co-receptors LDL receptor-related protein (LRP) 5 and LRP6, thereby antagonizing Wnt actions {13720, 14062, 15337}, such as induction of osteoblastogenesis, stimulation of pre-osteoblast replication, and inhibition of osteoblast apoptosis [25]-[27]. Thus, osteocytes exert negative feedback control of osteoblast number and bone formation via production of sclerostin.
###end p 5
###begin p 6
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-OBrien2">[28]</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido2">[29]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Langdahl1">[30]</xref>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Miao1">[31]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Ueno1">[32]</xref>
###xml 703 707 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Rodan1">[33]</xref>
###xml 708 712 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Suda1">[36]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Galli1">[37]</xref>
###xml 1146 1150 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Pfeilschifter1">[38]</xref>
###xml 1353 1357 1353 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido2">[29]</xref>
###xml 1359 1363 1359 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Jilka1">[39]</xref>
###xml 23 29 <span type="species:ncbi:9606">humans</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
Abundant evidence from humans and experimental animals indicates that parathyroid hormone (PTH) increases the rate of bone resorption, and thereby the rate of bone remodeling. Thus, chronic elevation of PTH levels increases bone resorption [28], [29] whereas patients with hypoparathyroidism [30] or rodents lacking PTH [31], [32] exhibit reduced bone resorption. The currently held view is that PTH stimulates osteoclast formation by binding to its receptor, PTH receptor 1 (PTHR1), on stromal/osteoblastic cells and thereby increases production of receptor activator of NFkB ligand (RANKL) and macrophage colony stimulating factor (M-CSF) and suppresses the RANKL decoy receptor osteoprotegerin (OPG) [33]-[36]. Consistent with this notion, removal of the PTH responsive region of the RANKL gene is sufficient to reduce the rate of bone resorption, mimicking the effects of hypoparathyroidism [37]. Chronic PTH elevation also increases osteoblast number and bone formation. This may occur indirectly through stimulation of bone resorption which releases growth factors embedded in the bone matrix and these in turn promote osteoblast formation [38]. Intermittent administration of PTH as a therapy to induce bone anabolism also increases osteoblast number, but the mechanisms are thought to be different from those involved with chronic PTH elevation [29], [39].
###end p 6
###begin p 7
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Parfitt2">[40]</xref>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Calvi1">[41]</xref>
Chronic PTH elevation, as in hyperparathyroidism, causes loss of cortical bone. Cancellous bone is also lost with secondary hyperparathyroidism caused by dietary calcium deficiency, but it is preserved or even increased in primary hyperparathyroidism or with activating mutations of PTHR1 [40], [41]. Thus, PTH always increases the rate of bone remodeling, but it can result in either loss or gain of cancellous bone mass depending on the balance between resorption and formation. The mechanisms underlying these different outcomes of PTH action are unknown.
###end p 7
###begin p 8
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Wysolmerski1">[42]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Miao2">[43]</xref>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Miao3">[44]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Martin1">[45]</xref>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
PTH related peptide (PTHrP) binds to PTHR1 and has important actions during development [42]. Recent genetic studies in mice demonstrate that PTHrP also acts postnatally to control bone mass [43], [44]. Thus, mice with PTHrP haploinsufficiency, or with deletion of the PTHrP gene specifically from osteoblasts, exhibit reduced bone formation due to increased osteoblast apoptosis. In addition, the number of osteoclasts is reduced in these animals most likely because of reduced RANKL expression. Thus, activation of PTHR1 by either PTH or PTHrP increases the rate of bone remodeling [45].
###end p 8
###begin p 9
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Keller1">[46]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Fermor1">[47]</xref>
###xml 394 409 <span type="species:ncbi:10090">transgenic mice</span>
We and others have recently determined that PTH inhibits the expression of the osteocyte specific gene Sost, raising the possibility that the hormone stimulates bone formation via direct actions on osteocytes [15], [46]. Consistent with this idea, expression of PTHR1 has been demonstrated in osteocytes [47]. Here we demonstrate that activation of PTHR1 signaling exclusively in osteocytes in transgenic mice is sufficient to decrease sclerostin expression, increase Wnt signaling, and increase bone mass. Unexpectedly, PTHR1 activation in osteocytes also accelerates the rate of bone remodeling. Remarkably, deletion of the Wnt co-receptor LRP5 attenuates the high bone mass phenotype induced by the transgene, but does not affect the increased remodeling. Thus, PTH signaling in osteocytes stimulates the accrual of bone mass and increases the rate of bone remodeling by LRP5-dependent and -independent mechanisms, respectively. Hence, the skeletal effects of PTH and PTHrP may be due in part to previously unrecognized actions of PTHR1 activation in osteocytes.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice Expressing a Constitutively Active PTHR1 in Osteocytes Exhibit High Bone Mass
###end title 11
###begin p 12
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Schipani1">[48]</xref>
###xml 286 295 286 295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 286 295 286 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g001"><bold>Figure 1A</bold></xref>
###xml 395 398 395 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Tatsumi1">[5]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kalajzic1">[49]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Lu1">[52]</xref>
###xml 557 566 557 566 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 557 566 557 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g001"><bold>Figure 1B</bold></xref>
###xml 767 771 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 773 777 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kalajzic1">[49]</xref>
###xml 779 783 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Yang1">[50]</xref>
###xml 915 936 915 936 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</bold>
###xml 915 936 915 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4"><bold>Materials and Methods</bold></xref>
###xml 938 947 938 947 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 938 947 938 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g001"><bold>Figure 1C</bold></xref>
###xml 982 992 982 992 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures 1C</bold>
###xml 982 992 982 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g001"><bold>Figures 1C</bold></xref>
###xml 997 1000 997 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s001">S1A</xref>
###xml 992 1000 992 1000 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and <xref ref-type="supplementary-material" rid="pone.0002942.s001">S1A</xref></bold>
###xml 1578 1582 1578 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 1584 1588 1584 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Keller1">[46]</xref>
###xml 112 127 <span type="species:ncbi:10090">transgenic mice</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 652 667 <span type="species:ncbi:10090">transgenic mice</span>
###xml 706 721 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1098 1113 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1193 1199 <span type="species:ncbi:10090">murine</span>
###xml 1284 1288 <span type="species:ncbi:10090">mice</span>
###xml 1434 1438 <span type="species:ncbi:10090">mice</span>
###xml 1651 1655 <span type="species:ncbi:10090">mice</span>
To determine whether hormonal signaling in osteocytes is sufficient to alter skeletal homeostasis, we generated transgenic mice expressing a constitutively active form of human PTHR1 [48] specifically in osteocytes using the dentin matrix protein-1 (DMP1) promoter (DMP1-caPTHR1 mice) (Figure 1A). This promoter was previously shown to direct osteocyte-specific expression of transgenes in mice [5], [49]-[52]. Expression of the DMP1-caPTHR1 transgene was detected in bone tissues (L5 vertebra and tibia), but not in kidney, liver, spleen, heart, or brain (Figure 1B). To confirm osteocyte-specific expression of the transgene, hemizygous DMP1-caPTHR1 transgenic mice were crossed with homozygous DMP1-GFP transgenic mice in which GFP is expressed only in osteocytes [15], [49], [50], and gene expression was examined in GFP-positive and GFP-negative cell populations obtained from neonatal calvaria as detailed in Materials and Methods (Figure 1C). In two independent experiments (Figures 1C and S1A), transcripts for the DMP1-caPTHR1 transgene were found only in cells obtained from DMP1-caPTHR1 transgenic mice and were highly enriched in the GFP-positive, osteocyte fraction. In contrast, murine PTHR1 mRNA levels were similar in GFP-positive and GFP-negative cell populations in mice with and without the DMP1-caPTHR1 transgene. Expression of the osteocyte-specific gene Sost was enriched in the GFP-positive cells obtained from mice with or without the DMP1-caPTHR1 transgene. Furthermore, consistent with previous findings demonstrating that PTH inhibits Sost expression [15], [46], Sost mRNA was lower in osteocytes obtained from DMP1-caPTHR1 mice. These results demonstrate that the DMP1-caPTHR1 transgene was expressed exclusively in osteocytes.
###end p 12
###begin title 13
###xml 38 42 <span type="species:ncbi:10090">Mice</span>
Generation of DMP1-caPTHR1 Transgenic Mice.
###end title 13
###begin p 14
###xml 524 526 524 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 228 234 <span type="species:ncbi:10090">murine</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 689 693 <span type="species:ncbi:10090">mice</span>
###xml 717 722 <span type="species:ncbi:9606">human</span>
###xml 730 736 <span type="species:ncbi:10090">murine</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
(A) Schematic representation of the DMP1-caPTHR1 transgene. The transgene contains the cDNA encoding the H223R constitutively active mutant of PTHR1 (caPTHR1) inserted downstream from a 12-kb DNA fragment containing 8 kb of the murine DMP1 5'-flanking region, first exon, first intron, and 17 bp of exon 2; a synthetic polyadenylation site was inserted downstream from the caPTHR1 sequence. Arrows indicate the sites recognized by primers used for genotyping. (B) Quantitative RT-PCR analysis of DMP1-caPTHR1 mRNA from the 5th lumbar vertebrae (L5), tibia, and soft tissues of 10.5-week-old mice, normalized to the housekeeping gene ribosomal protein S2. Bars represent the mean+/-SD of 4 mice. (C) Expression of the human PTHR1, murine PTHR1, and Sost determined by quantitative RT-PCR in freshly isolated osteoblast-enriched (GFP-) and osteocyte-enriched (GFP+) cell preparations obtained from neonatal mice without (WT) or with (TG) the DMP1-caPTHR1 transgene.
###end p 14
###begin p 15
###xml 124 134 124 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1B</bold>
###xml 124 134 124 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s001"><bold>Figure S1B</bold></xref>
###xml 232 241 232 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A</bold>
###xml 232 241 232 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g002"><bold>Figure 2A</bold></xref>
###xml 503 512 503 512 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 503 512 503 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g002"><bold>Figure 2B</bold></xref>
###xml 517 520 517 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s001">S1C</xref>
###xml 512 520 512 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and <xref ref-type="supplementary-material" rid="pone.0002942.s001">S1C</xref></bold>
###xml 714 724 714 724 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1D</bold>
###xml 714 724 714 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s001"><bold>Figure S1D</bold></xref>
###xml 829 838 829 838 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 829 838 829 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g002"><bold>Figure 2C</bold></xref>
###xml 1061 1070 1061 1070 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1061 1070 1061 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g002"><bold>Figure 2C</bold></xref>
###xml 1180 1197 1180 1197 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures 2D and 2E</bold>
###xml 1180 1197 1180 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g002"><bold>Figures 2D and 2E</bold></xref>
###xml 1297 1307 1297 1307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1E</bold>
###xml 1297 1307 1297 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s001"><bold>Figure S1E</bold></xref>
###xml 13 28 <span type="species:ncbi:10090">transgenic mice</span>
###xml 438 453 <span type="species:ncbi:10090">transgenic mice</span>
###xml 651 666 <span type="species:ncbi:10090">transgenic mice</span>
###xml 773 788 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1280 1295 <span type="species:ncbi:10090">transgenic mice</span>
DMP1-caPTHR1 transgenic mice were born at the expected Mendelian frequency, were fertile, exhibited normal size and weight (Figure S1B), but displayed increased radiodensity in regions of the skull and long bones at 4 weeks of age (Figure 2A). Serial measurement of bone mineral density (BMD) by dual-energy x-ray absorptiometry (DEXA) revealed a remarkable and progressive increase in bone mass in the appendicular and axial skeleton in transgenic mice of both sexes compared to wild type littermates (Figure 2B and S1C). Femoral BMD was 63% higher than wild type littermates at 8 weeks of age and 109% higher at 24 weeks. Increased bone mass in the transgenic mice was maintained until at least 8 months of age (Figure S1D). Micro-CT of femur and vertebra of 10-week-old transgenic mice confirmed the high bone mass phenotype (Figure 2C). Cross-sectional area of the femur at both the distal metaphysis and midshaft was elevated by approximately 2-fold. Increased bone was also observed in the calvaria, a bone that is formed by intramembranous ossification (Figure 2C). Abundant bone tissue and increased mineral was revealed by staining with hematoxylin & eosin or von Kossa (Figures 2D and 2E). This high bone mass phenotype was also present in a second line of DMP1-caPTHR1 transgenic mice (Figure S1E).
###end p 15
###begin title 16
###xml 13 17 <span type="species:ncbi:10090">Mice</span>
DMP1-caPTHR1 Mice Exhibit High Bone Mass.
###end title 16
###begin p 17
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
(A) Radiographs of 4-week-old female wild type (WT) and DMP1-caPTHR1 transgenic (TG) mice. (B) Femoral and spinal BMD in WT and TG female mice, measured at 4 wk intervals up to 24 wks of age. Symbols represent the mean+/-SD of 5 mice. * p<0.05 vs. WT mice at each time point. (C) Representative longitudinal and cross-sectional micro-CT images of femur, 4th lumbar vertebra, and calvaria obtained from 10.5-week-old female WT and TG mice. (D) Hematoxylin and eosin staining of tibial and (E) von Kossa staining of femoral bone sections from 10.5-week-old WT and TG mice.
###end p 17
###begin title 18
###xml 13 17 <span type="species:ncbi:10090">Mice</span>
DMP1-caPTHR1 Mice Exhibit Elevated Bone Remodeling
###end title 18
###begin p 19
###xml 141 150 141 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S2</bold>
###xml 141 150 141 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s002"><bold>Figure S2</bold></xref>
###xml 198 207 198 207 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S3</bold>
###xml 198 207 198 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s003"><bold>Figure S3</bold></xref>
###xml 728 743 728 743 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A and B</bold>
###xml 728 743 728 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3A and B</bold></xref>
###xml 749 757 749 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s007">Table S1</xref>
###xml 743 757 743 757 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, and <xref ref-type="supplementary-material" rid="pone.0002942.s007">Table S1</xref></bold>
###xml 1049 1058 1049 1058 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C</bold>
###xml 1049 1058 1049 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3C</bold></xref>
###xml 1210 1219 1210 1219 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3D</bold>
###xml 1210 1219 1210 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3D</bold></xref>
###xml 1312 1321 1312 1321 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3E</bold>
###xml 1312 1321 1312 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3E</bold></xref>
###xml 1546 1555 1546 1555 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3E</bold>
###xml 1546 1555 1546 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3E</bold></xref>
###xml 1674 1682 1674 1682 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1</bold>
###xml 1674 1682 1674 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s007"><bold>Table S1</bold></xref>
###xml 1848 1857 1848 1857 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3F</bold>
###xml 1848 1857 1848 1857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3F</bold></xref>
###xml 2122 2131 2122 2131 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3F</bold>
###xml 2122 2131 2122 2131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3F</bold></xref>
###xml 2131 2132 2131 2132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 2231 2240 2231 2240 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S4</bold>
###xml 2231 2240 2231 2240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s004"><bold>Figure S4</bold></xref>
###xml 2272 2293 2272 2293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Methods</bold>
###xml 2295 2302 2295 2302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s006">Text S1</xref>
###xml 2446 2455 2446 2455 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3G</bold>
###xml 2446 2455 2446 2455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3G</bold></xref>
###xml 2508 2517 2508 2517 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3G</bold>
###xml 2508 2517 2508 2517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3G</bold></xref>
###xml 2761 2770 2761 2770 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3H</bold>
###xml 2761 2770 2761 2770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g003"><bold>Figure 3H</bold></xref>
###xml 45 60 <span type="species:ncbi:10090">transgenic mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 711 726 <span type="species:ncbi:10090">transgenic mice</span>
###xml 939 954 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1237 1252 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1657 1672 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1842 1846 <span type="species:ncbi:10090">mice</span>
###xml 2105 2120 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2744 2759 <span type="species:ncbi:10090">transgenic mice</span>
The high bone mass phenotype of DMP1-caPTHR1 transgenic mice was present as early as 3 days after birth, had progressed by 3.5 weeks of age (Figure S2), and appeared maximal before 12 weeks of age (Figure S3). To determine the cellular basis of the increased bone mass, we performed histomorphometric measurements of cancellous bone of the distal femur in 3.5-week-old mice. This age was selected for histomorphometric analysis because, in contrast to mice at older ages, a large amount of cancellous bone surface was available for analysis and the cellular processes leading to increased bone mass must have still been occurring. Cancellous bone area and trabecular width were increased in femoral bone of the transgenic mice (Figure 3A and B, and Table S1); however, trabecular spacing and number were not significantly different from wild type littermates. Both osteoblast and osteoclast perimeters were elevated by more than 2-fold in transgenic mice, whereas the number of osteocytes per cancellous bone area (osteocyte density) was unchanged (Figure 3C). This increase in the numbers of osteoclasts and osteoblasts, and thus the rate of bone remodeling, was reflected by a decrease in quiescent surface (Figure 3D). The DMP1-PTHR1 transgenic mice also exhibited diffuse incorporation of the fluorochromes (Figure 3E). Therefore, quantification of the rate of bone formation was not possible. The presence of diffuse labels could be due to rapid bone formation leading to woven bone, which was indeed revealed by polarized light microscopy (Figure 3E). However, abnormal mineralization cannot be excluded since osteoid surface was also elevated in the transgenic mice (Table S1). Nevertheless, and consistent with the elevated osteoblast number and expected high bone formation rate, circulating osteocalcin was elevated in DMP1-caPTHR1 mice (Figure 3F). Moreover, in line with the increase in osteoclast perimeter, plasma levels of carboxy-terminal crosslinked telopeptide of type I collagen (CTX) and urinary levels of deoxypyridinoline (DPD), markers of bone resorption, were also elevated in the transgenic mice (Figure 3F). No significant changes were found in circulating levels of calcium, inorganic phosphate, or PTH (Figure S4), measured as indicated in the Supplementary Methods (Text S1) section. The increase in osteoblast number induced by the transgene was associated with a decrease in the prevalence of osteoblast apoptosis (Figure 3G). In contrast, osteocyte survival was not affected (Figure 3G). The number of mesenchymal progenitors or committed osteoblast progenitors in the bone marrow, as measured by colony forming units (CFU)-fibroblasts (CFU-F) or CFU-osteoblasts (CFU-OB), respectively, was not increased in the transgenic mice (Figure 3H). These results indicate that PTHR1 activation in osteocytes leads to an increased rate of bone remodeling with a positive balance resulting in more bone, associated with reduced prevalence of osteoblast apoptosis.
###end p 19
###begin title 20
###xml 24 28 <span type="species:ncbi:10090">Mice</span>
DMP1-caPTHR1 Transgenic Mice Have Increased Bone Turnover.
###end title 20
###begin p 21
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 137 139 <span type="species:ncbi:10090">TG</span>
###xml 395 397 <span type="species:ncbi:10090">TG</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
###xml 644 648 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 811 815 <span type="species:ncbi:10090">mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 875 879 <span type="species:ncbi:10090">mice</span>
(A-D) Histomorphometric measurements were determined in the distal femur, excluding the growth plate, of 3.5-week-old DMP1-caPTHR1 mice (TG) and wild type littermates (WT). Both sexes were included. Bone area (A), trabecular architecture (B), osteoblast perimeter, osteoclast perimeter, and osteocyte density (C), and quiescent surface (D) are shown. (E) Distal femoral cancellous bone of WT or TG mice viewed with epifluorescence to reveal calcein and alizarin labels or with polarized light with a rose quartz plate to reveal collagen architecture (x200). (F) Serum osteocalcin, serum CTX, and urinary DPD were measured in 3.5- to 5-week-old mice. (G) Osteoblast and osteocyte apoptosis measured in femoral sections from 3.5-week-old mice. (H) CFU-F and CFU-OB obtained from bone marrow cells of 4.5-week-old mice. Bars represent the mean+/-SD of 3-5 mice. * p<0.05 vs. WT mice.
###end p 21
###begin title 22
###xml 90 94 <span type="species:ncbi:10090">Mice</span>
Sost and Sclerostin Expression are Reduced and Wnt Signaling is Increased in DMP1-caPTHR1 Mice
###end title 22
###begin p 23
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 203 219 203 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S5A and B</bold>
###xml 203 219 203 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s005"><bold>Figure S5A and B</bold></xref>
###xml 225 246 225 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Methods</bold>
###xml 443 453 443 453 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S5C</bold>
###xml 443 453 443 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002942.s005"><bold>Figure S5C</bold></xref>
###xml 665 683 665 683 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A, B and C</bold>
###xml 665 683 665 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g004"><bold>Figure 4A, B and C</bold></xref>
###xml 919 926 913 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 928 937 922 931 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4D</bold>
###xml 928 937 922 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g004"><bold>Figure 4D</bold></xref>
###xml 1032 1036 1023 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Yochum1">[53]</xref>
###xml 1037 1041 1028 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Rousset1">[55]</xref>
###xml 1088 1097 1079 1088 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4E</bold>
###xml 1088 1097 1079 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g004"><bold>Figure 4E</bold></xref>
###xml 1158 1162 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Glass2">[56]</xref>
###xml 1164 1168 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Holmen1">[57]</xref>
###xml 1261 1270 1249 1258 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4F</bold>
###xml 1261 1270 1249 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g004"><bold>Figure 4F</bold></xref>
###xml 1427 1436 1415 1424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4F</bold>
###xml 1427 1436 1415 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g004"><bold>Figure 4F</bold></xref>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 488 503 <span type="species:ncbi:10090">transgenic mice</span>
###xml 755 759 <span type="species:ncbi:10090">mice</span>
###xml 797 801 <span type="species:ncbi:10090">mice</span>
###xml 1071 1086 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1410 1425 <span type="species:ncbi:10090">transgenic mice</span>
Quantitative RT-PCR and in situ hybridization demonstrated an increase in the mRNAs encoding osteocalcin, collagen 1a1, and osteopontin in bones from DMP1-caPTHR1 mice compared to wild type littermates (Figure S5A and B, and Supplementary Methods section). Furthermore, expression of the osteoclast-specific genes cathepsin K, tartrate resistant acid phosphatase (TRAPase), and calcitonin receptor was also elevated in the transgenic animals (Figure S5C). On the other hand, DMP1-caPTHR1 transgenic mice exhibited a striking decrease in Sost transcripts and sclerostin protein, as determined by quantitative RT-PCR, Western blot analysis, and immunohistochemistry (Figure 4A, B and C). Increased beta-galactosidase activity in bones from the DMP1-caPTHR1 mice crossed with Wnt-responsive reporter mice (TCF-betaGal) demonstrated that decreased Sost and sclerostin expression were associated with elevated Wnt signaling in vivo (Figure 4D). Furthermore, expression of the Wnt/beta-catenin target genes Axin 2, SMAD6, BMP4, and naked [53]-[55] was elevated in DMP1-caPTHR1 transgenic mice (Figure 4E). OPG, another gene regulated by Wnt/beta-catenin signaling [56], [57], was also slightly elevated, although this increase did not reach statistical significance (Figure 4F). In contrast, RANKL and M-CSF, cytokines that control the magnitude of osteoclast formation, were significantly increased in DMP1-caPTHR1 transgenic mice (Figure 4F).
###end p 23
###begin title 24
###xml 103 107 <span type="species:ncbi:10090">Mice</span>
Sost and Sclerostin Expression are Decreased and Wnt Signaling is Increased in DMP1-caPTHR1 Transgenic Mice.
###end title 24
###begin p 25
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 309 311 <span type="species:ncbi:10090">TG</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 459 461 <span type="species:ncbi:10090">TG</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 860 864 <span type="species:ncbi:10090">mice</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
(A) Quantitative RT-PCR analysis of Sost mRNA in tibia from 9-week-old DMP1-caPTHR1 mice and wild type littermates (n = 3). Both sexes were included. (B) Sclerostin protein levels were determined by Western blot analysis of lysates from the 6th lumbar vertebrae of 9-week-old wild type (WT) and DMP1-caPTHR1 (TG) mice. Each lane contains protein lysate from a single mouse. (C) Anti-sclerostin immunohistochemistry in ulnae sections from 10.5-week-old WT and TG mice. (D) beta-galactosidase activity was measured in lysates of femurs obtained from 4.5-week-old TCF-betagal reporter mice with and without the DMP1-caPTHR1 transgene, and is expressed as relative luminescence units (RLU)/200 mg protein (n = 3-5 mice/group). Quantitative RT-PCR analysis of the indicated Wnt target genes (E), and OPG, RANKL, and M-CSF (F), in tibia from 8-week-old DMP1-caPTHR1 mice and wild type littermates. Bars represent the mean+/-SD of 3 mice. * p<0.05 vs. WT mice.
###end p 25
###begin title 26
###xml 108 112 <span type="species:ncbi:10090">Mice</span>
LRP5 Signaling Contributes to the Increased Bone Mass, but not to the Increased Remodeling, of DMP1-caPTHR1 Mice
###end title 26
###begin p 27
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-ClementLacroix1">[58]</xref>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Gong1">[60]</xref>
###xml 872 881 868 877 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 872 881 868 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g005"><bold>Figure 5A</bold></xref>
###xml 1018 1027 1014 1023 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 1018 1027 1014 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g005"><bold>Figure 5A</bold></xref>
###xml 1180 1195 1176 1191 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B and C</bold>
###xml 1180 1195 1176 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g005"><bold>Figure 5B and C</bold></xref>
###xml 1392 1401 1388 1397 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</bold>
###xml 1392 1401 1388 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g005"><bold>Figure 5C</bold></xref>
###xml 1663 1672 1659 1668 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 1663 1672 1659 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g006"><bold>Figure 6A</bold></xref>
###xml 1829 1838 1825 1834 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 1829 1838 1825 1834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g005"><bold>Figure 5A</bold></xref>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 808 812 <span type="species:ncbi:10090">mice</span>
###xml 910 925 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
###xml 1750 1754 <span type="species:ncbi:10090">mice</span>
To determine whether inhibition of Sost gene expression in osteocytes and the resulting increase in Wnt signaling was indeed responsible for the high bone mass phenotype exhibited by DMP1-caPTHR1 mice, these mice were crossed with mice lacking the Wnt co-receptor LRP5 (LRP5-/-), which display a low bone mass phenotype due to reduced osteoblast number and activity [58]-[60]. Sost mRNA expression in DMP1-caPTHR1;LRP5-/- mice was still suppressed compared to LRP5-/- mice lacking the transgene (0.37+/-0.23 versus 2.00+/-1.16, p<0.05), eliminating the possibility that the absence of LRP5 interfered with the ability of the transgene to decrease Sost in osteocytes. Serial BMD measurements confirmed the progressive increase in bone mass between 4 and 12 weeks of age in the femur and spine of DMP1-caPTHR1 mice in a LRP5+/+ background compared to wild type littermates (Figure 5A). In contrast, DMP1-caPTHR1 transgenic mice in a LRP5-/- background exhibited BMD similar to LRP5-/- littermates lacking the transgene (Figure 5A). The blunting of the effect of the transgene in mice lacking LRP5 was confirmed by Von Kossa staining and high resolution micro-CT at 12 weeks of age (Figure 5B and C). Micro-CT images also revealed that the transgene was still able to increase cancellous bone in animals lacking LRP5, however this effect was greatly reduced compared to animals expressing LRP5 (Figure 5C). This persistent increase in bone induced by the transgene in animals lacking LRP5 could be due to increased Wnt signaling through LRP6. In addition, bone material density as measured by micro-CT was decreased by the transgene regardless of the LRP5 genotype (Figure 6A). This may explain why the increased cancellous bone in DMP1-caPTHR1;LRP5-/- mice detected by micro-CT did not result in increased BMD as measured by DEXA (Figure 5A).
###end p 27
###begin title 28
###xml 49 53 <span type="species:ncbi:10090">Mice</span>
###xml 72 76 <span type="species:ncbi:10090">Mice</span>
The High Bone Mass Phenotype of the DMP1-caPTHR1 Mice is Ameliorated in Mice Lacking the Wnt Co-Receptor LRP5.
###end title 28
###begin p 29
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
(A) Serial analysis of BMD in the femur and spine of LRP5+/+ and LRP-/- mice, with and without the DMP1-caPTHR1 transgene. Both sexes were included. Bars represent the mean+/-SD of 3-5 mice/group. * p<0.05 vs. LRP5+/+ mice without the transgene. # p<0.05 vs. LRP+/+ mice without the transgene. (B) Von Kossa staining of femurs and lumbar vertebrae of 12-week-old LRP5+/+ and LRP-/- mice, with and without the DMP1-caPTHR1 transgene. (C) High resolution micro-CT scans of distal femora from LRP5+/+ and LRP-/- mice, with and without the DMP1-caPTHR1 transgene.
###end p 29
###begin title 30
###xml 51 55 <span type="species:ncbi:10090">Mice</span>
The High Bone Remodeling Phenotype of DMP1-caPTHR1 Mice does not Require LRP5.
###end title 30
###begin p 31
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
(A) Osteocalcin and CTX measured in plasma from 12-week-old LRP5+/+ and LRP-/- mice, with and without the DMP1-caPTHR1 transgene. Both sexes were included. (B) Bone material density as determined by micro-CT analysis of femurs from LRP5+/+ and LRP-/- mice, with and without the DMP1-caPTHR1 transgene. Bars represent the mean+/-SD of 3-5 mice/group. * p<0.05 vs. LRP5+/+ mice without the transgene; # p<0.05 vs. LRP5+/+ mice with the transgene. (C) Representative images of histologic sections showing calcein and alizarin double labeling in femurs from LRP5+/+ and LRP-/- mice with and without the DMP1-caPTHR1 transgene.
###end p 31
###begin p 32
###xml 181 190 181 190 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6B</bold>
###xml 181 190 181 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g006"><bold>Figure 6B</bold></xref>
###xml 442 457 442 457 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B and C</bold>
###xml 442 457 442 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g005"><bold>Figure 5B and C</bold></xref>
###xml 621 630 621 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6C</bold>
###xml 621 630 621 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g006"><bold>Figure 6C</bold></xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bouxsein1">[61]</xref>
###xml 768 772 768 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Feng1">[51]</xref>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
Despite the reduced ability of the transgene to increase bone mass in the absence of LRP5, circulating levels of CTX and osteocalcin remained elevated in DMP1-caPTHR1;LRP5-/- mice (Figure 6B). However, the increase in osteocalcin was significantly lower than the one induced by the transgene in the LRP5+/+ background. Consistent with a high rate of bone resorption, the DMP1-caPTHR1;LRP5-/- mice still exhibited increased cortical porosity (Figure 5B and C). Furthermore, DMP1-caPTHR1;LRP5-/- mice showed the same abundant and diffuse fluorochrome incorporation observed in DMP1-caPTHR1 mice with intact LRP5 signaling (Figure 6C). This phenomenon, as well as the reduced bone material density, may be due to the formation of woven bone [61], abnormal mineralization [51], or both.
###end p 32
###begin p 33
Taken together, these results suggest that activation of the PTH receptor in osteocytes results in two separate effects: one that leads to increased bone mass and that depends in part on LRP5 signaling to favor bone formation, and another that results in increased bone remodeling independent of LRP5 signaling.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Neuman1">[62]</xref>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Parfitt3">[63]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Keller1">[46]</xref>
###xml 784 787 784 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Tatsumi1">[5]</xref>
###xml 789 793 789 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kalajzic1">[49]</xref>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Lu1">[52]</xref>
###xml 801 805 801 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Ye1">[64]</xref>
###xml 1280 1284 1280 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Liu1">[34]</xref>
###xml 1286 1290 1286 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Calvi1">[41]</xref>
###xml 1438 1446 1438 1446 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7</bold>
###xml 1438 1446 1438 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g007"><bold>Figure 7</bold></xref>
The concept that PTH can act directly on osteocytes was proposed in the 1970's based on evidence that injected radiolabeled-PTH localizes in osteocytes and that the hormone changes osteocyte morphology [62], [63]. Recently we and others have shown that PTH suppresses the expression of the osteocyte-specific product sclerostin, an antagonist of Wnt signaling [15], [46]. This evidence, together with the well documented role of Wnt signaling in osteoblastogenesis, suggested a mechanism by which PTH may control the production of osteoblasts through actions on osteocytes. In the present report, we have addressed the functional consequences of PTH actions in osteocytes by taking advantage of a fragment of the DMP1 promoter that confers osteocyte-specific expression of transgenes [5], [49], [52], [64]. The evidence presented herein demonstrates that PTH receptor signaling exclusively in osteocytes is sufficient to increase osteoblast number and dramatically increase bone mass via down-regulation of sclerostin and thereby elevation of LRP5 signaling. Remarkably, activation of PTHR1 in osteocytes also caused an increase in bone resorption, and thereby the rate of bone remodeling. This effect of PTH was previously attributed to its actions on stromal/osteoblastic cells [34], [41]. Thus, our findings reveal for the first time that osteocytes could be the targets and mediators of the two most important effects of PTH on bone (Figure 7). Whether this is the case outside the context of the genetic manipulation used here will await osteocyte-specific deletion of the PTH receptor.
###end p 35
###begin title 36
PTHR1 Signaling in Osteocytes Leads to Increased Bone Mass and Remodeling via Distinct Mechanisms.
###end title 36
###begin p 37
In the proposed model, PTHR1 signaling in osteocytes activates at least two distinct pathways: one leading to increased bone mass and the other leading to increased bone remodeling. Suppression of Sost/sclerostin and activation of LRP5 signaling increase osteoblast numbers and are required for the increase in bone mass. The elevation of bone resorption is independent of the Sclerostin/LRP5 pathway. The question mark indicates uncertainty of the cellular source of RANKL and M-CSF (osteocytes versus stromal/osteoblastic cells).
###end p 37
###begin p 38
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido2">[29]</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Jilka1">[39]</xref>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Jilka2">[65]</xref>
###xml 970 974 970 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bodine1">[66]</xref>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Ellies1">[68]</xref>
###xml 1026 1034 1026 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1076 1080 1076 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Almeida1">[27]</xref>
###xml 755 759 <span type="species:ncbi:10090">mice</span>
###xml 841 845 <span type="species:ncbi:10090">mice</span>
PTH can clearly increase bone mass when administered intermittently, and this effect has been attributed by us to a direct and potent anti-apoptotic effect of the hormone on osteoblasts [29], [39], [65]. In the present report, we determined that the increased osteoblast number and bone formation caused by PTH signaling exclusively in osteocytes is also associated with decreased osteoblast apoptosis. Attenuation of osteoblast apoptosis in our model can be readily explained by unleashing Wnt signaling secondary to suppression of Sost expression. Indeed, several studies demonstrate that Wnt signaling increases osteoblast number and bone formation at least in part by inhibiting osteoblast apoptosis. Specifically, the increased bone mass observed in mice deficient in the Wnt antagonist secreted frizzled related protein-1 (SFRP-1), or mice expressing a LRP5 mutant (G171V) unable to bind sclerostin, is associated with decreased osteoblast and osteocyte apoptosis [66]-[68]. Moreover, direct activation of Wnt signaling in vitro prevents apoptosis of osteoblastic cells [27].
###end p 38
###begin p 39
###xml 90 94 <span type="species:ncbi:10090">mice</span>
Besides the anti-apoptotic effects of Wnts in the increased bone mass of the DMP1-caPTHR1 mice, the unleashing of Wnt signaling in this model may have had additional effects on cells of the osteoblastic lineage. We did not find an increase in the number of CFU-OB, indicating that such additional effects did not influence the very early stages of osteoblastogenesis. It is entirely feasible, however, that Wnts also increased osteoblast number by attenuating the apoptosis, stimulating the differentiation, or increasing the proliferation of the progeny of CFU-OB, or a combination of these mechanisms.
###end p 39
###begin p 40
Targeted activation of the PTH receptor exclusively in osteocytes also increased osteoclast number and bone resorption and these changes were accompanied by an elevation of the levels of RANKL and M-CSF, the two essential signals for osteoclastogenesis. Whether osteocytes are the source of these cytokines, or whether an osteocyte-derived product stimulated the expression of these cytokines in a paracrine fashion by altering their production in stromal/osteoblastic cells, awaits further studies.
###end p 40
###begin p 41
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Weinstein3">[69]</xref>
###xml 570 578 570 578 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 570 578 570 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002942-g002"><bold>Figure 2</bold></xref>
###xml 727 731 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Weinstein3">[69]</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 659 667 <span type="species:ncbi:9606">patients</span>
###xml 787 793 <span type="species:ncbi:9606">humans</span>
The results of the present studies with genetically modified mice could well be relevant to the mechanisms underlying the changes in bone cells that occur with hyperparathyroidism. Several skeletal features of the DMP1-caPTHR1 mice are similar to those found in patients with hyperparathyroidism, including a high rate of bone remodeling, increased cancellous bone, and increased cortical porosity [69]. Indeed, the cortical porosity and cancellous bone were increased to such an extent that the junction between cortical and cancellous bone could not be distinguished (Figure 2). Erosion of the cortex, as well as the presence of woven bone, is also seen in patients with secondary hyperparathyroidism in renal osteodystrophy [69]. Therefore, some of the skeletal changes that occur in humans with high levels of PTH may be due to direct actions of the hormone on osteocytes.
###end p 41
###begin p 42
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
The striking bone gain in DMP1-caPTHR1 mice and the blunting of this effect in mice lacking LRP5 suggest that PTH signaling in osteocytes promotes a positive balance within each remodeling unit via suppression of Sost. Consistent with this contention, in preliminary studies we found that DMP1-caPTHR1 mice that also harbor a DMP1-Sost transgene do not exhibit high bone mass, indicating that suppression of Sost is indeed required for the anabolic effect of the DMP1-caPTHR1 transgene (data not shown).
###end p 42
###begin p 43
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido2">[29]</xref>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 1231 1235 1231 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Pyrah1">[70]</xref>
###xml 1354 1358 1354 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Calvi1">[41]</xref>
###xml 1360 1364 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Calvi2">[71]</xref>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
###xml 1243 1258 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1441 1445 <span type="species:ncbi:10090">mice</span>
In contrast to our findings demonstrating dramatic bone anabolism with PTHR1 signaling exclusively in osteocytes, chronic elevation of PTH systemically leads to bone loss or to only a modest increase in cancellous bone. This difference may be explained by actions of the hormone on mature osteoblasts and osteoblast precursors that counter-balance osteocyte-mediated effects on bone formation. Specifically, the prevalence of osteoblast apoptosis is decreased in DMP1-caPTHR1 mice but not with chronic elevation of PTH [29]. Yet, sclerostin is suppressed, and Wnt signaling is elevated, in both conditions [15]. Therefore, it appears that Wnt signaling is not able to inhibit apoptosis in a cell in which the PTHR1 is continuously activated. Consistent with this, osteocyte apoptosis was not suppressed in DMP1-caPTHR1 mice likely because the pro-survival effects of Wnts were overridden by the simultaneous PTHR1 signal, whereas osteoblast apoptosis was suppressed because osteoblasts receive only Wnt pro-survival signals. Chronic elevation of PTH may also suppress osteoblast differentiation and lead to accumulation of immature osteoblasts. This effect could account for the marrow fibrosis found in severe hyperparathyroidism [70] and in transgenic mice expressing a constitutively active PTHR1 under the control of a collagen 1a1 promoter fragment [41], [71]. Maturational arrest of osteoblastic cells was not observed in DMP1-caPTHR1 mice, indicating that this effect is due to PTHR1 activation in cells other than osteocytes.
###end p 43
###begin p 44
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bodine1">[66]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Babij1">[67]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Li1">[19]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Ke1">[20]</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 324 339 <span type="species:ncbi:10090">transgenic mice</span>
Resorption was still elevated in DMP1-caPTHR1 mice in a LRP5-null background, supporting the contention that increased Wnt signaling in these mice does not contribute to the increased rate of bone remodeling. This is consistent with evidence that models of elevated Wnt signaling, such as SFRP-1 knockout mice or G171V-LRP5 transgenic mice, do not exhibit increased bone resorption [66], [67]. Moreover, administration of an anti-sclerostin antibody as well as deletion of the Sost gene, maneuvers which increase Wnt signaling through both LRP5 and LRP6, increased bone formation but did not alter bone resorption [19], [20].
###end p 44
###begin p 45
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Keller1">[46]</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Sawakami1">[72]</xref>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Robling1">[73]</xref>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
In contrast to chronic elevation of PTH, daily injections of the hormone induce bone anabolism. This mode of administration of PTH is associated with a transient suppression of sclerostin [15], [46], which could result in increased Wnt signaling. Although daily injections of PTH induced equivalent increases in femoral BMD in LRP5-null and wild type mice [72], [73], these animals retained LRP6. Thus, the possibility that suppression of sclerostin contributes to the anabolic action of intermittent PTH administration will require additional studies.
###end p 45
###begin p 46
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Miao3">[44]</xref>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Chen1">[74]</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Sawakami1">[72]</xref>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Robling1">[73]</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
The decreased bone formation exhibited by mice lacking PTHrP in osteoblastic cells demonstrates that under physiological conditions osteoblast/osteocyte-derived PTHrP promotes bone formation in part by stimulating osteoblast differentiation and survival [44]. Our studies raise the possibility that PTHrP promotes bone formation postnatally via suppression of sclerostin and stimulation of Wnt signaling. In particular, PTHrP might contribute to the maintenance of skeletal mass by mechanical forces. Indeed, PTHrP expression is increased in response to mechanical stimulation of osteoblastic and osteocytic cell lines [74]. And, we have shown that the anabolic response of bone loading is associated with reduced sclerostin expression and that it requires LRP5 signaling [72], [73]. Taken together these findings raise the possibility that local increase in PTHrP induced by mechanical loading activates PTHR1 in osteocytes, thereby reducing sclerostin expression and increasing bone formation.
###end p 46
###begin p 47
In conclusion, this study expands the prevailing view of osteocytes as mediators of the response of bone to mechanical forces to one in which these cells also orchestrate changes in bone mass and the rate of remodeling in response to hormones.
###end p 47
###begin title 48
Materials and Methods
###end title 48
###begin title 49
###xml 38 42 <span type="species:ncbi:10090">Mice</span>
###xml 68 72 <span type="species:ncbi:10090">Mice</span>
Generation of DMP1-caPTHR1 Transgenic Mice and Cross with LRP5-Null Mice
###end title 49
###begin p 50
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Schipani1">[48]</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kalajzic1">[49]</xref>
###xml 883 886 883 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 892 896 892 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-ClementLacroix1">[58]</xref>
###xml 981 984 981 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 993 996 993 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 13 28 <span type="species:ncbi:10090">transgenic mice</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 266 272 <span type="species:ncbi:10090">murine</span>
###xml 335 341 <span type="species:ncbi:9986">rabbit</span>
###xml 485 500 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 598 603 <span type="species:ncbi:10090">mouse</span>
###xml 694 699 <span type="species:ncbi:10090">mouse</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
###xml 817 821 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
###xml 997 1001 <span type="species:ncbi:10090">mice</span>
###xml 1051 1055 <span type="species:ncbi:10090">mice</span>
###xml 1208 1212 <span type="species:ncbi:10090">mice</span>
DMP1-caPTHR1 transgenic mice were generated using a DNA construct encoding the H223R mutant of the human PTHR1 [48] inserted downstream from a 12 kb DNA fragment containing 8 kb of the 5'-flanking region, the first exon, the first intron, and 17 bp of exon 2 of the murine DMP1 gene [49]. In addition, a 140 bp fragment containing the rabbit beta-globin polyadenylation sequence was inserted downstream from the H223R cDNA. The DNA sequence of the transgene is available upon request. Transgenic mice were produced by microinjection of purified DNA into pronuclei of C57BL/6 mice at the transgenic mouse core facility of the University of Arkansas for Medical Sciences. DMP1-caPTHR1 transgenic mouse colonies were maintained by breeding mice hemizygous for the transgene with wild type C57BL/6 mice. All DMP1-caPTHR1 mice used in these studies were hemizygous for the transgene. LRP5-/- mice [58] were crossed with DMP1-caPTHR1 mice and the progeny were intercrossed to obtain LRP5+/+ and LRP5-/- mice with and without the DMP1-caPTHR1 transgene. All mice were fed a regular diet (Harlan/Teklad #7001) and water ad libitum and maintained on a 12-hr light/dark cycle. Protocols involving genetically modified mice and their wild type littermates were approved by the Institutional Animal Care and Use Committees of the University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System.
###end p 50
###begin title 51
Analysis of Skeletal Phenotypes
###end title 51
###begin p 52
###xml 142 146 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Fu1">[75]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-OBrien2">[28]</xref>
###xml 593 597 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Glatt1">[76]</xref>
###xml 851 854 847 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Weinstein1">[6]</xref>
###xml 1106 1110 1102 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Sawakami1">[72]</xref>
###xml 1266 1270 1262 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Parfitt4">[77]</xref>
###xml 1325 1332 1321 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1389 1392 1385 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Weinstein1">[6]</xref>
###xml 1394 1398 1390 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Jilka3">[78]</xref>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Radiographic images were obtained from anesthetized mice using a Faxitron X-ray system (AxR model MIIONH, Faxitron X-ray Corp., Wheeling, IL) [75]. BMD was determined by DEXA using a PIXImus densitometer (G.E. Medical Systems, Lunar Division, Madison, WI) as previously described [28]. BMD measurements included the entire thoracic and lumbar spine (spinal BMD) or the entire femur (femoral BMD). For micro-CT analysis, bones were dissected, cleaned of soft tissue and stored in 70% ethanol until analyzed using a Scanco model microCT40 instrument (Scanco Medical AG, Basserdorf, Switzerland) [76]. For histomorphometric analysis, femurs were dissected, fixed, and embedded in methyl methacrylate. Static histomorphometric analysis of non-decalcified bone sections was performed in the distal femur, avoiding the growth plate, as previously described [6]. Fluorochrome labeling of the bones was performed by intraperitoneal injections of calcein (20 mg/kg, Sigma Chemical, St. Louis, MO, USA) and alizarin (20 mg/kg, Sigma) administered 8 and 3 days before sacrifice, respectively, as previously described [72]. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research [77]. Detection of apoptotic osteoblasts and osteocytes by in situ nick-end labeling was performed as previously described [6], [78]. Mineralized bone was visualized in non-decalcified, plastic-embedded sections using the von Kossa stain, and decalcified, paraffin embedded bone sections were stained with hematoxylin and eosin, using standard histological procedures.
###end p 52
###begin title 53
Bone Turnover Markers
###end title 53
###begin p 54
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido2">[29]</xref>
Plasma osteocalcin and CTX were measured using an enzyme radiometric assay (Biomedical Technologies, Soughton, MA) and an enzyme linked immunosorbant assay (Immunodiagnostic Systems Inc., Fountain Hills, AZ), respectively [29].
###end p 54
###begin title 55
Osteocyte Isolation
###end title 55
###begin p 56
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kalajzic1">[49]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido2">[29]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kalajzic2">[79]</xref>
###xml 20 35 <span type="species:ncbi:10090">transgenic mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 352 357 <span type="species:ncbi:10090">mouse</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
Homozygous DMP1-GFP transgenic mice (provided by D. W. Rowe) [49] were crossed with hemizygous DMP1-caPTHR1 mice to generate DMP1-GFP-positive offspring with and without the DMP1-caPTHR1 transgene. Calvaria cells were isolated from 3- to 6-day-old mice using a modification of a previously described protocol [15], [29], [79]. Briefly, bones from each mouse were individually subjected to serial trypsin/collagenase digestions of 20 minutes each and fractions 2 through 9 were collected. Cells obtained from mice exhibiting the same genotype were pooled and GFP-expressing cells (enriched in osteocytes) were separated from GFP-negative cells (enriched in osteoblasts) by immediately subjecting the cell suspension to sorting using a FACSAria flow cytometer (BD Biosciences, San Jose, CA) at the University of Arkansas for Medical Sciences Flow Cytometry Core Facility. RNA was isolated from the cells immediately after sorting.
###end p 56
###begin title 57
Gene Expression Studies
###end title 57
###begin title 58
Quantitative PCR
###end title 58
###begin p 59
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Fu1">[75]</xref>
###xml 409 413 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Livak1">[80]</xref>
Total RNA was purified from cells or tissues using Ultraspec reagent (Biotecx Laboratories, Houston, TX), according to the manufacturer's instructions. Taqman quantitative RT-PCR was performed as previously described [75] using primer probe sets from Applied Biosystems (Foster City, CA). Relative mRNA expression levels were normalized to the house-keeping gene ribosomal protein S2 using the DeltaCt method [80].
###end p 59
###begin title 60
Western Blot Analysis
###end title 60
###begin p 61
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 307 311 <span type="species:ncbi:9925">goat</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
###xml 433 439 <span type="species:ncbi:9986">rabbit</span>
###xml 445 449 <span type="species:ncbi:9925">goat</span>
Immunoblots were performed on protein lysates prepared from vertebral bone (L6) as previously described [15]. One hundred microg of protein lysate from individual mice was separated on a 10% SDS gel and then transferred to Immobilon membrane (Millipore, Billerica, MA). The membrane was then incubated with goat polyclonal anti-mouse sclerostin antibody (1:100 in 5% non fat milk) overnight at 4degreesC, followed by incubation with rabbit anti-goat-HRP secondary antibody (1:2000 in 5% milk) for 1 hour at room temperature, and then developed with enhanced chemiluminescence (Pierce Biotechnology, Inc., Rockford, IL).
###end p 61
###begin title 62
Immunohistochemistry
###end title 62
###begin p 63
###xml 494 498 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Bellido1">[15]</xref>
###xml 500 504 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Robling1">[73]</xref>
###xml 133 137 <span type="species:ncbi:9925">goat</span>
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
###xml 231 237 <span type="species:ncbi:9986">rabbit</span>
###xml 257 263 <span type="species:ncbi:9986">rabbit</span>
###xml 269 273 <span type="species:ncbi:9925">goat</span>
###xml 373 379 <span type="species:ncbi:9986">rabbit</span>
Ulnae were fixed in neutral buffered formalin, decalcified, and then embedded in paraffin. Eight microm sections were incubated with goat polyclonal anti-mouse sclerostin antibody (R&D Systems, Minneapolis, MN) diluted 1:100 in 2% rabbit serum, followed by rabbit anti-goat-HRP conjugated secondary antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) diluted 1:200 in 2% rabbit serum, and developed with a DAB substrate-chromogen system (Dako Corp., Carpinteria, CA), as previously described [15], [73]. Sections were washed and counterstained with methyl green.
###end p 63
###begin title 64
TCF-betaGAL Reporter Gene Assay
###end title 64
###begin p 65
###xml 78 82 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Dasgupta1">[81]</xref>
###xml 464 468 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Kousteni2">[82]</xref>
###xml 23 38 <span type="species:ncbi:10090">transgenic mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
Homozygous TCF-betaGAL transgenic mice (Jackson Laboratories, Bar Harbor, ME) [81], which contain a beta-galactosidase reporter gene under the control of a TCF-responsive promoter, were crossed with hemizygous DMP1-caPTHR1 mice to obtain TCF-betaGAL mice with or without the DMP1-caPTHR1 transgene. beta-galactosidase activity was determined in femurs from 31-day-old mice using the Galacto-Light kit (Applied Biosystems, Foster City, CA), as previously described [82]. Bones were homogenized for 20 seconds in lysis buffer and protein content was determined using the BioRad DC protein assay kit (Hercules, CA). beta-galactosidase activity was expressed as relative fluorescent units/200 microg protein.
###end p 65
###begin title 66
Assay for osteoblast progenitors
###end title 66
###begin p 67
###xml 188 189 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002942-Jilka4">[83]</xref>
###xml 64 79 <span type="species:ncbi:10090">transgenic mice</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Bone marrow cells were isolated from 4.5-week-old wild type and transgenic mice (8 mice per group). Four sets of 2 samples from different mice were pooled and seeded at a density of 0.3x106 cells/cm2. CFU-F and CFU-OB were developed in the presence of 1 mM L-ascorbic acid phosphate magnesium salt n-hydrate (A2P, Wako Chemicals USA, Richmond, VA) for 10 and 25 days, respectively, as previously published [83]. For the determination of CFU-F, colonies were stained for alkaline phosphatase and counterstained with hematoxylin. Colonies of cells containing a minimum of 20 cells were designated as CFU-F. For the determination of CFU-OB, cultures were stained using Von Kossa staining to visualize and enumerate colonies containing mineralized bone matrix.
###end p 67
###begin title 68
Statistical Analysis
###end title 68
###begin p 69
Data were analyzed using SigmaStat (SPSS Science, Chicago, IL). All values are reported as the mean+/-SD. Differences between group means were evaluated with Student's t test or ANOVA.
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin p 71
###xml 38 42 <span type="species:ncbi:10090">Mice</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 90 96 <span type="species:ncbi:10090">murine</span>
###xml 297 312 <span type="species:ncbi:10090">transgenic mice</span>
###xml 368 383 <span type="species:ncbi:10090">transgenic mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
###xml 644 648 <span type="species:ncbi:10090">mice</span>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
Generation of DMP1-caPTHR1 Transgenic Mice (A) Expression of the human PTHR1 (transgene), murine PTHR1, and Sost, normalized to ribosomal protein S2, was determined by quantitative RT-PCR in osteoblast-enriched (GFP-) and osteocyte-enriched (GFP+) cell preparations from wild type or DMP1-caPTHR1 transgenic mice. (B) Total body weight of female and male DMP1-caPTHR1 transgenic mice and wild type littermates measured every 4 weeks up to 24 weeks of age. Symbols represent the mean+/-S.D. of 5 mice. (C) Serial measurement of femoral and spinal BMD of male DMP1-caPTHR1 mice and wild type littermates. Symbols represent the mean+/-S.D. of 3-5 mice. * p<0.05 vs. WT mice for each time point. (D) Micro-CT image of femurs from 8-month-old wild type and DMP1-caPTHR1 mice. (E) Total, femoral, and spinal BMD in 9-week-old WT and DMP1-caPTHR1 male mice from an independent transgenic line, 559. Bars represent the mean+/-S.D. of 5 mice. * p<0.05 vs. WT mice.
###end p 71
###begin p 72
(0.19 MB TIF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
###xml 72 76 <span type="species:ncbi:10090">Mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 189 191 <span type="species:ncbi:10090">TG</span>
###xml 481 483 <span type="species:ncbi:10090">TG</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
Micro-CT Analysis of 3-Day-Old and 3.5-Week-Old DMP1-caPTHR1 Transgenic Mice (A) Representative longitudinal and cross-sectional micro-CT images of femurs from 3-day-old DMP1-caPTHR1 mice (TG) and wild type littermates (WT). Three animals per genotype were analyzed. The total bone volume per femur was measured. * indicates p<0.05 vs wild type littermates. (B) Longitudinal and cross-sectional micro-CT images of femurs, 5th lumbar vertebra, and calvaria from 3.5-week-old WT and TG mice.
###end p 74
###begin p 75
(0.35 MB TIF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 126 130 <span type="species:ncbi:10090">Mice</span>
Hematoxylin & Eosin Staining of Longitudinal Sections of Femoral Diaphysis of 4-, 8-, and 12-Week-Old DMP1-caPTHR1 Transgenic Mice Decalcified, paraffin embedded femurs were longitudinally sectioned and stained with hematoxylin and eosin. Bars indicate 0.1 mm.
###end p 77
###begin p 78
(2.00 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
###xml 81 96 <span type="species:ncbi:10090">transgenic mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
Circulating levels of Calcium, Phosphate and PTH are not altered in DMP1-caPTHR1 transgenic mice Plasma levels of (A) total calcium, (B) inorganic phosphate, and (C) PTH in DMP1-caPTHR1 mice and wild type littermates. Bars are mean+/-S.D. (A) n = 4 wild type and 5 transgenic 3.5-week-old; (B) n = 11 wild type and 16 transgenic 2.5-month-old mice; and (C) n = 5 wild type and 7 transgenic 2-month-old mice.
###end p 80
###begin p 81
(0.09 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 75 79 <span type="species:ncbi:10090">Mice</span>
###xml 173 188 <span type="species:ncbi:10090">transgenic mice</span>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
Osteoblast and Osteoclast Markers are Increased in DMP1-caPTHR1 Transgenic Mice (A) Quantitative RT-PCR analysis of osteoblastic genes in tibia from 9-week-old DMP1-caPTHR1 transgenic mice and wild type littermates. Bars represent the mean+/-SD of 3 mice. *p<0.05 vs. WT mice. (B) In situ hybridization of tibia sections from 10.5-week-old mice with the indicated probes. (C) Quantitative RT-PCR of osteoclast-specific genes in tibia of 9-week-old mice. Bars represent the mean+/-SD of 3 mice. * p<0.05 vs. WT mice.
###end p 83
###begin p 84
(1.03 MB TIF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
(0.03 MB DOC)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
(0.04 MB DOC)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin p 90
###xml 249 252 249 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
The authors thank Kanan Vyas, Priscilla E. Cazer, Rebecca Wynne, William Webb, Chester Wicker, Stuart Berryhill, Keith Condon, and Vaida Glatt for technical assistance, Steve Harris for providing the DMP1 promoter, Matt Warman for providing the LRP5-/- mice, and A.M. Parfitt for insightful suggestions.
###end p 90
###begin title 91
References
###end title 91
###begin article-title 92
Modeling and remodeling: how bone cells work together.
###end article-title 92
###begin article-title 93
The osteocyte.
###end article-title 93
###begin article-title 94
Osteocytes as Dynamic, Multifunctional Cells.
###end article-title 94
###begin article-title 95
The structure of bone tissues and the cellular control of their deposition.
###end article-title 95
###begin article-title 96
Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.
###end article-title 96
###begin article-title 97
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone.
###end article-title 97
###begin article-title 98
Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.
###end article-title 98
###begin article-title 99
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity.
###end article-title 99
###begin article-title 100
###xml 77 82 <span type="species:ncbi:9606">human</span>
Identification of apoptotic changes in osteocytes in normal and pathological human bone.
###end article-title 100
###begin article-title 101
###xml 73 78 <span type="species:ncbi:9606">human</span>
The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone.
###end article-title 101
###begin article-title 102
###xml 39 42 <span type="species:ncbi:10116">rat</span>
The role of estrogen in the control of rat osteocyte apoptosis.
###end article-title 102
###begin article-title 103
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.
###end article-title 103
###begin article-title 104
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
###end article-title 104
###begin article-title 105
Sclerostin ss an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
###end article-title 105
###begin article-title 106
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
###end article-title 106
###begin article-title 107
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
###end article-title 107
###begin article-title 108
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
###end article-title 108
###begin article-title 109
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
###end article-title 109
###begin article-title 110
###xml 44 48 <span type="species:ncbi:10090">Mice</span>
Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength.
###end article-title 110
###begin article-title 111
Bone anabolism achieved by reducing sclerostin bioavailability with an anti-sclerostin antibody.
###end article-title 111
###begin article-title 112
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
###end article-title 112
###begin article-title 113
SOST is a ligand for LRP5/LRP6 and a WNT signaling inhibitor.
###end article-title 113
###begin article-title 114
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
###end article-title 114
###begin article-title 115
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
###end article-title 115
###begin article-title 116
In vivo analysis of Wnt signaling in bone.
###end article-title 116
###begin article-title 117
Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.
###end article-title 117
###begin article-title 118
Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT.
###end article-title 118
###begin article-title 119
###xml 117 121 <span type="species:ncbi:10090">mice</span>
IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
###end article-title 119
###begin article-title 120
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.
###end article-title 120
###begin article-title 121
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Bone histomorphometry in hypoparathyroid patients treated with vitamin D.
###end article-title 121
###begin article-title 122
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Skeletal abnormalities in PTH-null mice are influenced by dietary calcium.
###end article-title 122
###begin article-title 123
###xml 128 132 <span type="species:ncbi:10116">rats</span>
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
###end article-title 123
###begin article-title 124
Role of osteoblasts in hormonal control of bone resorption - a hypothesis.
###end article-title 124
###begin article-title 125
###xml 27 33 <span type="species:ncbi:10090">murine</span>
Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro.
###end article-title 125
###begin article-title 126
###xml 108 114 <span type="species:ncbi:10090">murine</span>
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
###end article-title 126
###begin article-title 127
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families [In Process Citation].
###end article-title 127
###begin article-title 128
Targeted deletion of a distant transcriptional enhancer of the RANKL gene reduces bone remodeling and increases bone mass.
###end article-title 128
###begin article-title 129
Modulation of type b transforming growth factor activity in bone cultures by osteotropic hormones.
###end article-title 129
###begin article-title 130
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.
###end article-title 130
###begin article-title 131
Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism.
###end article-title 131
###begin article-title 132
Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone.
###end article-title 132
###begin article-title 133
Physiological actions of PTH and PTHrP. V. Epidermal, mammary, reproductive, and pancreatic tissue.
###end article-title 133
###begin article-title 134
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice.
###end article-title 134
###begin article-title 135
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.
###end article-title 135
###begin article-title 136
Osteoblast-derived PTHrP is a physiological regulator of bone formation.
###end article-title 136
###begin article-title 137
SOST is a target gene for PTH in bone.
###end article-title 137
###begin article-title 138
###xml 103 107 <span type="species:ncbi:10116">rats</span>
PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats.
###end article-title 138
###begin article-title 139
A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia.
###end article-title 139
###begin article-title 140
Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene.
###end article-title 140
###begin article-title 141
Dentin matrix protein 1 gene cis-regulation: Use In osteocytes to characterize local responses to mechanical loading in vitro and In vivo.
###end article-title 141
###begin article-title 142
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
###end article-title 142
###begin article-title 143
DMP1-targeted Cre expression in odontoblasts and osteocytes.
###end article-title 143
###begin article-title 144
Serial analysis of chromatin occupancy identifies beta-catenin target genes in colorectal carcinoma cells.
###end article-title 144
###begin article-title 145
###xml 82 87 <span type="species:ncbi:9606">human</span>
Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells.
###end article-title 145
###begin article-title 146
Naked cuticle targets dishevelled to antagonize Wnt signal transduction.
###end article-title 146
###begin article-title 147
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
###end article-title 147
###begin article-title 148
Essential role of beta-catenin in postnatal bone acquisition.
###end article-title 148
###begin article-title 149
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice.
###end article-title 149
###begin article-title 150
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor.
###end article-title 150
###begin article-title 151
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
###end article-title 151
###begin article-title 152
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Ovariectomy-induced bone loss varies among inbred strains of mice.
###end article-title 152
###begin article-title 153
The metabolism of labeled parathyroid hormone. IV. Autoradiographic studies.
###end article-title 153
###begin article-title 154
The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation.
###end article-title 154
###begin article-title 155
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Dentin matrix protein 1 (Dmp1) deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype.
###end article-title 155
###begin article-title 156
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.
###end article-title 156
###begin article-title 157
###xml 117 121 <span type="species:ncbi:10090">mice</span>
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice.
###end article-title 157
###begin article-title 158
###xml 18 22 <span type="species:ncbi:10090">mice</span>
High bone mass in mice expressing a mutant LRP5 gene.
###end article-title 158
###begin article-title 159
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
###end article-title 159
###begin article-title 160
Clinical use of bone biopsy.
###end article-title 160
###begin article-title 161
Primary hyperparathyroidism.
###end article-title 161
###begin article-title 162
Constitutively active PTH/PTHrP receptor in odontoblasts alters odontoblast and ameloblast function and maturation.
###end article-title 162
###begin article-title 163
The WNT co-receptor LRP5 is essential for skeletal mechanotransduction, but not for the anabolic bone response to parathyroid hormone treatment.
###end article-title 163
###begin article-title 164
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
###end article-title 164
###begin article-title 165
Stretch-Induced PTH-Related Protein Gene Expression in Osteoblasts.
###end article-title 165
###begin article-title 166
Parathyroid hormone controls receptor activator of NFkB ligand gene expression via a distant transcriptional enhancer.
###end article-title 166
###begin article-title 167
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Age-related changes in trabecular architecture differ in female and male C57BL/6J mice.
###end article-title 167
###begin article-title 168
Bone histomorphometry: standardization of nomenclature, symbols, and units.
###end article-title 168
###begin article-title 169
Apoptosis in bone cells.
###end article-title 169
###begin article-title 170
Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage.
###end article-title 170
###begin article-title 171
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 171
###begin article-title 172
Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation.
###end article-title 172
###begin article-title 173
Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor.
###end article-title 173
###begin article-title 174
###xml 55 61 <span type="species:ncbi:10090">murine</span>
Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption.
###end article-title 174
###begin p 175
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 175
###begin p 176
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 219 226 <span type="species:ncbi:4097">Tobacco</span>
Funding: This research was supported by the National Institutes of Health (R01 DK076007, R01 AR049794, P01 AG13918, and S10-RR023710), the Department of Veterans Affairs, and University of Arkansas for Medical Sciences Tobacco Settlement funds.
###end p 176

